News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center

Articles by Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center

Advice for Community Oncologists on Treating HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Treatments for Relapsed/Refractory HCL in Pipeline

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

The Role of CD22-targeted Immunotoxins in HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Landscape Change in the Treatment of Relapsed/Refractory HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Historical Treatment for Relapsed/Refractory HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

When to Not Use Combination and the Need for Bone Marrow Biopsy in HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Combination First-line Therapy in Hairy Cell Leukemia

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Determining When to Treat and First-Line Therapy for HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Differential Diagnosis and Molecular Tests in Identifying HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Signs and Tests for Diagnosis and Prognosis of HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Molecular Genetic Changes for Hairy Cell Leukemia

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Introduction and Epidemiology of Hairy Cell Leukemia

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Latest Updated Articles

Differential Diagnosis and Molecular Tests in Identifying HCL
Published: June 30th 2020 | Updated:
Advice for Community Oncologists on Treating HCL
Published: June 30th 2020 | Updated:
$Landscape Change in the Treatment of Relapsed/Refractory HCL$
Landscape Change in the Treatment of Relapsed/Refractory HCL
Published: June 30th 2020 | Updated:
Molecular Genetic Changes for Hairy Cell Leukemia
Published: June 30th 2020 | Updated:
Signs and Tests for Diagnosis and Prognosis of HCL
Published: June 30th 2020 | Updated:
When to Not Use Combination and the Need for Bone Marrow Biopsy in HCL
Published: June 30th 2020 | Updated:

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma

Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies